Skip to main content
Premium Trial:

Request an Annual Quote

Merck Acquires Rosetta Inpharmatics for $620 Million in Stock

NEW YORK, May 11 – Merck has agreed to acquire Rosetta Inpharmatics in a stock-for-stock transaction worth $620 million, the companies said Friday.

The tax-free reorganization will swap each share of Rosetta stock for 0.2352 shares of Merck stock, giving a value of $18 per share of Rosetta stock, an 82 percent premium on Thursday’s closing price.

"In our continuous efforts to enhance our drug discovery research capabilities, we found Rosetta to be an excellent acquisition candidate because of its genomics expertise and its ability to add significant value to Merck's demonstrated scientific capabilities,"  Richard Kender, Merck's vice president of corporate development and licensing, said in a statement.

Rosetta will operate as a wholly-owned subsidiary and independent unit within Merck Research Laboratories, keeping its facilities in Kirkland and Bothell, Wash. Rosetta’s current chairman and CEO, Stephen Friend, will report to Anthony Ford-Hutchinson, executive vice president for worldwide basic research at Merck, as president of Rosetta and vice president for basic research at Merck.

"Joining Merck allows us to move into our next stage of development, which is beyond providing tools and software and into direct involvement with drug discovery," Friend said in a statement.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.